InvestorsHub Logo
icon url

Jhawker

12/15/17 4:05 PM

#208443 RE: frrol #208437

I suspect secondary endpoints to be close to interim data. Remember if our placebo numbers had been in line with historical we would be having a different outlook all together.
icon url

williamssc

12/15/17 5:53 PM

#208455 RE: frrol #208437

I bet they are carefully going over data from each trial site comparing results. I remember the p2a results saw a problem with one of those sites.
icon url

To infinity and beyond!

12/16/17 9:07 AM

#208507 RE: frrol #208437

yes agree completely

viable not spectacular

sad but true, and so it goes.

maybe it is a better acne drug? we shall see
icon url

DesireToLearn

12/16/17 9:42 AM

#208512 RE: frrol #208437

Key is reduced chances of incident rate. If it also reduces duration, then even better. Will make it a more attractive drug.